- Home
- AIRT vs MNOV Comparison
AIRT vs MNOV Comparison
Compare AIRT & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRT | MNOV |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | United States |
| Employees | 646 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.8M | 67.9M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | AIRT | MNOV |
|---|---|---|
| Price | $28.06 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 11.1K | ★ 37.0K |
| Earning Date | 02-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $18.35 | $1.17 |
| 52 Week High | $34.49 | $1.96 |
Technical Indicators
Market Signals| Indicator | AIRT | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 58.70 | 47.47 |
| Support Level | $20.80 | $1.30 |
| Resistance Level | $30.36 | $1.46 |
| Average True Range (ATR) | 1.45 | 0.04 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 62.30 | 33.33 |
Price Performance
Historical ComparisonAbout AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include overnight air cargo, ground support equipment, commercial aircraft, engines and parts, digital solutions, and regional airline. The company generates maximum revenue from the overnight air cargo segment.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.